3 Results for "

exhausted CD8+ T cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "exhausted CD8+ T cells" in MCE Product Catalog:

Cat. No.: HY-N0600
CAS No.: 62025-50-7
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P991911

Research Areas:  

Cancer

PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8 + tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 + T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .
loading...
    loading...
Cat. No.: HY-P992433
Target:  

LILRB

Research Areas:  

Cancer

OR502 is a humanized IgG1 monoclonal antibody targeting LILRB2 (ILT4/CD85d), with a Kd value of 1.18 nM. OR502 binds to LILRB2 with high affinity and blocks its interaction with HLA class I ligands, relieving myeloid cell-mediated immunosuppression, restoring CD8 + T cell function, and reprogramming the immunosuppressive macrophage phenotype, thereby simultaneously enhancing both innate and adaptive antitumor immune responses. OR502 can be used in the research of cancers and advanced cancers (including melanoma, non-small cell lung cancer, sarcoma/soft tissue cancer, and urothelial carcinoma) .
loading...
    loading...